KalVista Pharmaceuticals, Inc.
HealthcareNASDAQ:KALV · NASDAQ Global Market
+$0.00 today
Vol 4.26M · Avg 3.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6060.0%
avg 496.3%
ROIC
-58.9%
avg -56.0%
ROA
-49.0%
avg -41.8%
Analysis
ROE is currently the strongest return metric at 6060.0% versus its period average of 496.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Benjamin L. Palleiko | Chief Executive Officer & Director | $1.15M | — | 60 | $0.00 | <0.01% |
Paul K. Audhya | Chief Medical Officer | $773,445.00 | — | 54 | $0.00 | <0.01% |
Christopher Yea | Chief Development Officer | $708,532.00 | — | 62 | $0.00 | <0.01% |
Brian Piekos | Chief Financial Officer | $638,486.00 | — | 51 | $0.00 | <0.01% |
Bilal Arif | Chief Operating Officer | $572,458.00 | — | 54 | $0.00 | <0.01% |
Brian Krex | General Counsel | — | — | 58 | $0.00 | <0.01% |
Rachel Morten | Senior Vice President of Regulatory Affairs & QA | — | — | — | — | — |
Jarrod Aldom | Vice President of Corporate Communications | — | — | — | — | — |
Ryan Baker | Head of Investor Relations | — | — | — | — | — |
Christopher L. Hamblett | Senior Vice President of Corporate Development | — | — | — | $0.00 | <0.01% |
Linea Aspesi | Chief People Officer | — | — | 56 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
42
$7.07M
Net Sentiment
$7.07M
Net selling
Most Active
Palleiko Benjamin L
12 transactions
1–10 of 42
Analysis
Insiders reported 0 buys worth $0.00 and 42 sells worth $7.07M over the last 12 months. That adds up to net selling of $7.07M. Palleiko Benjamin L was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +53.6% | +58.3% (13yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +53.6% over three years. Forward estimates point to Revenue at +58.3% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Omeros Corporation
NASDAQ:OMER
$632.20M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages KALV?
KalVista Pharmaceuticals, Inc. (KALV) lists 11 active executives. The top listed executive is Benjamin L. Palleiko, Chief Executive Officer & Director.
Are KALV insiders buying or selling?
Recent insider activity shows net selling of $30.70M.
Explore More
Continue the stock analysis
Jump to another research area for this company.